Apps like the GLP-1 app bring together injection schedules, protein intake targets, hydration tracking, and side-effect monitoring all in one place
You may be a candidate if: You have documented excess visceral fat with imaging or waist circumference criteria You have features of metabolic syndrome elevated triglycerides, insulin resistance, impaired fasting glucose You have evidence of GH-axis insufficiency or age-related GH decline (low IGF-1) You have not achieved adequate visceral fat reduction through lifestyle modification alone You are being treated for HIV-associated lipodystrophy (the FDA-approved indication) You are not pregnant and do not have active malignancy both are absolute contraindications Lab workup typically includes: Fasting IGF-1 level Fasting glucose and insulin (HOMA-IR for insulin resistance) Full lipid panel Hemoglobin A1c Liver function tests Baseline CT or MRI for VAT quantification (in research settings) Meto's Comprehensive Metabolic Panel covers the core biomarkers fasting glucose, fasting insulin, lipid panel, liver markers, and inflammation markers giving your provider the baseline data needed to evaluate your candidacy accurately
But I would even go a step further than that and say even people that think of themselves as being overweight or obese and might physically be obese have more, potentially have more muscle mass because of carrying around that additional weight
Gut-brain communication by distinct sensory neurons differently controls feeding and glucose metabolism
Rotate injection sites to avoid local irritation
Actualmente, Mounjaro (tirzepatida) no est disponible como tratamiento oral, ya que solo existe en forma de inyeccin
